OncoMatch

OncoMatch/Clinical Trials/NCT07038096

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Is NCT07038096 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including ZG006 and ZG005 for small cell lung cancer.

Phase 1/2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdNCT07038096Data as of Jun 2026Location: China

Treatment: ZG006 · ZG005This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

ZG006ZG005

Cancer type

Small Cell Lung Cancer

Neuroendocrine Tumor

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 70

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07038096 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 70 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify